Nebenwirkungen · Pegasys
Pegasys 90 micrograms solution for injection in pre-filled syringe Pegasys 135 micrograms solution for injection in pre-filled syringe Pegasys 180 micrograms solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 19
HOS-109835 · Präparat HOS-093265
Table 9 summarises the undesirable effects reported with Pegasys monotherapy in CHB or CHC adult patients and with Pegasys in combination with ribavirin in CHC patients. Undesirable effects reported in clinical studies are grouped according to frequency as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1 000 to < 1/100), rare (≥ 1/10 000 to < 1/1 000), very rare (< 1/10 000). For spontaneous reports of undesirable effects from post-marketing experience, the frequency is not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in decreasing order of seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T12:00:00Z · SHA-256 d1a2dc533bd5ba4d4a21ad6973e4498c4ffde781c784ae67bbeeda36922e6382 · Passage dd5aaa3c6c08874e6a8f6c1be5c3a7c06673604e3d7ffd0fc66da9f93613f8f3 · Zeichen 4692–5349 im Abschnitt